Fem-Dophilus^® contains two patented and clinically documented probiotic strains, Lacticaseibacillus rhamnosus GR-1^®‡ and Limosilactobacillus reuteri RC-14^®‡, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1^® and RC-14^® to colonize and promote healthy vaginal and urinary tract health.* A special manufacturing process protects the probiotic strains in Fem-Dophilus^® from stomach acid and enhances probiotic bacterial survival to the lower intestine.

‡Updates based on official taxonomy reclassification.

GR-1^®/RC-14^® and VAGINAL FLORA (also called microbiota)

In one of the randomized clinical trials, 75% of women in the GR-1^®/RC-14^® probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement.